PMID- 10673522
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20221109
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 18
IP  - 4
DP  - 2000 Feb
TI  - Predictive role of interphase cytogenetics for survival of patients with multiple 
      myeloma.
PG  - 804-12
AB  - PURPOSE: Recent metaphase cytogenetic studies suggested that specific chromosomal 
      abnormalities are of prognostic significance in patients with multiple myeloma 
      (MM). Because the true incidence of chromosomal abnormalities in MM is much 
      higher than that detected by metaphase analysis, we used interphase fluorescence 
      in situ hybridization (FISH) to determine the prognostic value of specific 
      chromosomal aberrations. PATIENTS AND METHODS: Bone marrow plasma cells from 89 
      previously untreated patients with MM were studied consecutively by FISH to 
      detect the deletions of 13q14, 17p13, and 11q and the presence of 
      t(11;14)(q13;q32). FISH results were analyzed in the context of clinical 
      parameters (response to treatment and survival after conventional-dose 
      chemotherapy), and a multivariate analysis of prognostic factors was performed. 
      RESULTS: By FISH, the deletion of 13q14 occurred in 40 patients (44.9%), deletion 
      of 17p13 in 22 (24.7%), and 11q abnormalities in 14 (15.7%; seven with t(11;14)). 
      Deletions of 13q14 and 17p13 were associated with poor response to induction 
      treatment (46.9% v 77.3% in those without deletions, P =.006 and 40.0% v 73.2%, P 
      =.008, respectively) and short median overall survival (OS) time (24.2 v 88.1 
      months, P =. 008 and 16.2 v 51.3 months, P =.008, respectively). Short median OS 
      time was also observed for patients with 11q abnormalities (13.1 v 41.6 months, P 
      =.02). According to the number of unfavorable cytogenetic features (deletion of 
      13q14, deletion of 17p13, and aberrations of 11q) that were present in each 
      patient (0 v 1 v 2 or 3), patients with significantly different OS times could be 
      discriminated from one another (102.4 v 29.6 v 13.9 months, P <.001, 
      respectively). CONCLUSION: For patients with MM who were treated with 
      conventional-dose chemotherapy, interphase FISH for 13q14, 17p13, and 11q 
      provides prognostically relevant information in addition to that provided by 
      standard prognostic factors. This observation may be considered for risk-adapted 
      stratifications of MM patients in future clinical trials.
FAU - Konigsberg, R
AU  - Konigsberg R
AD  - First Department of Internal Medicine, Divisions of Clinical Oncology, University 
      of Vienna, Vienna, Austria.
FAU - Zojer, N
AU  - Zojer N
FAU - Ackermann, J
AU  - Ackermann J
FAU - Kromer, E
AU  - Kromer E
FAU - Kittler, H
AU  - Kittler H
FAU - Fritz, E
AU  - Fritz E
FAU - Kaufmann, H
AU  - Kaufmann H
FAU - Nosslinger, T
AU  - Nosslinger T
FAU - Riedl, L
AU  - Riedl L
FAU - Gisslinger, H
AU  - Gisslinger H
FAU - Jager, U
AU  - Jager U
FAU - Simonitsch, I
AU  - Simonitsch I
FAU - Heinz, R
AU  - Heinz R
FAU - Ludwig, H
AU  - Ludwig H
FAU - Huber, H
AU  - Huber H
FAU - Drach, J
AU  - Drach J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Marrow Cells/pathology
MH  - Chromosome Aberrations/*genetics
MH  - Chromosome Deletion
MH  - Chromosome Disorders
MH  - Chromosomes, Human, Pair 11/genetics
MH  - Chromosomes, Human, Pair 13/genetics
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Cytogenetics
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Interphase/*genetics
MH  - Male
MH  - Metaphase/genetics
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*genetics/pathology
MH  - Multivariate Analysis
MH  - Plasma Cells/pathology
MH  - Prognosis
MH  - Regression Analysis
MH  - Remission Induction
MH  - Survival Rate
MH  - Trisomy/genetics
EDAT- 2000/02/16 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/02/16 09:00
PHST- 2000/02/16 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/02/16 09:00 [entrez]
AID - 10.1200/JCO.2000.18.4.804 [doi]
PST - ppublish
SO  - J Clin Oncol. 2000 Feb;18(4):804-12. doi: 10.1200/JCO.2000.18.4.804.